Clinical Trial Update: Evaluate the Efficacy of Irinotecan Versus Oxaliplatin in the First-line Treatment of Refractory Metastatic Colorectal Cancer [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial comparing irinotecan to oxaliplatin as first-line therapy for refractory metastatic colorectal cancer; status is UNKNOWN.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Irinotecan (Irinotecan)
• OXALIPLATIN (Oxaliplatin)

Snippet

Sponsor: Peking University | Conditions: mCRC | Phase 2 | Status: UNKNOWN